

## eIF4A3-IN-5 biochemical

eIF4A3-IN-5

CATALOG #  
**AAA228112**


### PRODUCT SYNONYMS

eIF4A3-IN-5; eIF4A3-IN-5 biochemical


### PRODUCT SPECIFICATIONS

|                         |                                                                          |
|-------------------------|--------------------------------------------------------------------------|
| Purity/Purification     | 98%                                                                      |
| CAS                     | 2100145-31-9                                                             |
| Solubility              | <1mg/ml refers to the product slightly soluble or insoluble              |
| Preparation and Storage | Powder: -20 degree C for 3 years<br>In solvent: -80 degree C for 2 years |

### IMAGES



Structure  
FGFR1 inhibitor-2, CAS 2410612-08-5



Structure  
FGFR1 inhibitor-2, CAS 2410612-08-5

### ADDITIONAL INFORMATION

|                                                         |                                                                                                                                                                                                                                                                 |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Related Product Information for eIF4A3-IN-5 biochemical | eIF4A3-IN-5 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), such as eIF4AI and eIF4AII. eIF4A3-IN-5 has the potential for the research of eIF4A dependent diseases, including the research of cancer (extracted from patent US20170145026A1). |
| References                                              | 1. Ashraf-Uz-Zaman M, et al. Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. Eur J Med Chem. 2021;209:112866.                                        |

**For Research Use Only.** Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.